RT Journal Article
SR Electronic
T1 Qualitative assessment of SARS-CoV-2-specific antibody avidity by lateral flow immunochromatographic IgG/IgM antibody assay
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.23.20138016
DO 10.1101/2020.06.23.20138016
A1 Valdivia, Arantxa
A1 Torres, Ignacio
A1 Huntley, Dixie
A1 Alcaraz, María Jesús
A1 Albert, Eliseo
A1 Colomina, Javier
A1 Ferrer, Josep
A1 Carratalá, Arturo
A1 Navarro, David
YR 2020
UL http://medrxiv.org/content/early/2020/06/23/2020.06.23.20138016.abstract
AB Qualitative assessment of SARS-CoV-2-specific antibody avidity was conducted using an urea (6M) dissociation test performed on a lateral flow immunochromatographic IgG/IgM device. We included a total of 76 serum specimens collected from 57 COVID-19 patients, of which 39 tested positive for both IgG and IgM and 37 only for IgG. Sera losing IgG reactivity after urea treatment (n=28) were drawn significantly earlier (P=0.04) after onset of symptoms than those which preserved it (n=48). This assay may be helpful to estimate the time of acquisition of infection in patients with mild to severe COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo public or private funds were used for the current studyAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The current study was approved by the Ethics Committee of Hospital Clinico Universitario INCLIVA (2020-04)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author, [author initials], upon reasonable request